We bring the most sensitive biophysical assays to the high-throughput screening world. Our integrated biophysics platform combines lab automation with on-the-fly data analysis, allowing our customers to screen up to a million compounds within weeks, harnessing the power of direct binding assays.

Step Pharma is a clinical stage precision oncology company. Dencatistat (STP938) is a first in class, oral, selective CTPS1 inhibitor currently in Phase I/II clinical development in essential thrombocythemia, biomarker selected solid tumours and relapsed/refractory lymphoma.